Latest news with #CT-P72
Korea Herald
09-05-2025
- Business
- Korea Herald
Celltrion logs strongest Q1 sales
South Korean biopharmaceutical firm Celltrion reported record first-quarter revenue and a sharp jump in profit, as robust global demand for its next-generation biosimilars improved margins. Operating profit soared a whopping 870 percent from a year earlier to 149.4 billion won ($107 million) in the January-March period, while consolidated revenue rose 14.2 percent to 841.9 billion won, the South Korean biopharmaceutical firm said Friday. The earnings boost was attributed to the end of amortization costs tied to past mergers, enhanced inventory management and strong performance from high-margin products. Sales of key biosimilars, including Remsima SC, Yuflyma and Vegzelma, climbed more than 62 percent from a year earlier. Yuflyma, a treatment for autoimmune diseases, posted more than 100 billion won in quarterly sales for the first time, rising 1.6 times year-on-year. Vegzelma, a cancer treatment, secured a 28 percent prescription share in Europe's oncology biosimilar market, despite its relatively late market entry. Celltrion plans to launch four new high-margin biosimilars in the second half of the year and begin full-scale production of titer-enhanced products. The company expects revenue from new and follow-up therapies to make up over 60 percent of total sales by year-end. In drug development, Celltrion's multispecific antibody CT-P72 demonstrated strong tumor suppression and low toxicity in preclinical studies presented at the 2025 American Association for Cancer Research meeting. 'We've laid the groundwork for both quantitative and qualitative growth this year through strong performance from our next-generation biosimilars and cost-efficiency gains,' a company official said. 'With upcoming product launches and a solid new drug pipeline, we will continue to focus efforts on sustained growth.'
Business Insider
28-04-2025
- Business
- Business Insider
Abpro Holdings, Celltrion unveils preclinical data for ABP-102/CT-P72
Abpro Holdings (ABP) and Celltrion unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the American Association for Cancer Research, AACR, Annual Meeting 2025, in the New Drugs on the Horizon session. Key Findings: Highly Selective Tumor Killing: ABP-102/CT-P72 achieves potent cytotoxicity in HER2-overexpressing breast and gastric cancer models while significantly reducing activity against HER2-low cells, addressing a key limitation of prior HER2-targeted T-cell engagers. Enhanced Tumor Growth Inhibition: In vivo studies showed ABP-102/CT-P72 had up to a two-fold increase in tumor suppression compared to a biosimilar of runimotamab, a benchmark HER2 x CD3 bispecific antibody. Reduced Cytokine Release: Engineered for functionally monovalent CD3 binding, ABP-102/CT-P72 minimizes cytokine-related toxicities, as demonstrated by reduced cytokine release in HER2-low cell models while maintaining potent cytotoxicity in HER2-high models. Improved Tolerability: Dose escalation studies in cynomolgus monkeys confirmed that ABP-102/CT-P72 was well tolerated, even at doses exceeding 180 times the maximum tolerated dose observed with the parental antibody, suggesting a broader therapeutic window. Stay Ahead of the Market:
